GNH USA

Europe — EMA

Mycophenolate Mofetil Tillomed

GNH USA supplies Mycophenolate Mofetil Tillomed (Mycophenolate Mofetil), an immunosuppressant for organ transplant rejection prevention and autoimmune

Mycophenolate Mofetil

Request sourcing

1
Pack/s

What is Mycophenolate Mofetil?

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Tillomed, is an immunosuppressant (antimetabolite) presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat selected autoimmune disorders in adult patients.

GNH USA supplies Mycophenolate Mofetil Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

What is Mycophenolate Mofetil used for?

Mycophenolate Mofetil is used in the management of immune‑mediated conditions where suppression of lymphocyte activity is required.

- Prevention of organ transplant rejection: reduces the risk of acute and chronic graft rejection. - Lupus nephritis: helps control renal inflammation and preserve kidney function. - ANCA‑associated vasculitis: contributes to disease remission and organ preservation.

What are the side effects of Mycophenolate Mofetil?

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Tremor: fine shaking of hands or limbs. - Fatigue: generalized feeling of tiredness.

Serious or Rare Side Effects: - Opportunistic infections: increased susceptibility to bacterial, viral, or fungal pathogens. - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Malignancy: heightened risk of lymphoproliferative disorders. - Severe liver injury: elevated transaminases or hepatitis. - Progressive multifocal leukoencephalopathy: rare demyelinating brain disease. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

What precautions apply to Mycophenolate Mofetil?

Careful monitoring and patient education are essential when using Mycophenolate Mofetil.

- Renal function: assess serum creatinine and adjust therapy as needed. - Hematologic parameters: regularly check complete blood count for cytopenias. - Infection risk: screen for active infections before initiating therapy. - Pregnancy: contraindicated (Category X); effective contraception required. - Vaccinations: avoid live vaccines during treatment. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

What does Mycophenolate Mofetil interact with?

Mycophenolate Mofetil may interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Rituximab: heightened infection risk when combined. - Live vaccines: risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum‑magnesium): may reduce absorption. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase mycophenolate exposure. - CYP3A4 inducers (e.g., rifampin): decrease drug levels, potentially reducing efficacy.

Frequently asked questions

What conditions is Mycophenolate Mofetil Tillomed used for?+
Mycophenolate Mofetil Tillomed is prescribed to prevent rejection of transplanted organs and to manage certain autoimmune diseases such as lupus nephritis and ANCA‑associated vasculitis. By suppressing the activity of T‑ and B‑lymphocytes, it helps maintain graft function and reduces inflammatory damage in these conditions.
How does Mycophenolate Mofetil work in the body?+
The drug blocks inosine monophosphate dehydrogenase, an enzyme essential for de novo guanosine nucleotide synthesis. Lymphocytes depend heavily on this pathway, so inhibition limits their proliferation and activation, leading to a dampened immune response that is useful in transplantation and autoimmunity.
What is the usual dose of Mycophenolate Mofetil Tillomed?+
The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and concomitant therapies. Healthcare professionals tailor the regimen to achieve optimal immunosuppression while minimizing adverse effects.
Is Mycophenolate Mofetil safe during pregnancy or breastfeeding?+
Mycophenolate Mofetil is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.
How do I order Mycophenolate Mofetil Tillomed from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Mycophenolate Mofetil compare with other immunosuppressants?+
Compared with calcineurin inhibitors such as tacrolimus or cyclosporine, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination regimens to provide synergistic immunosuppression while potentially reducing the dose‑related toxicities of calcineurin agents.
What are the recommended storage conditions for Mycophenolate Mofetil Tillomed?+
The product should be stored at ambient temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.
How is Mycophenolate Mofetil Tillomed administered?+
Mycophenolate Mofetil Tillomed is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency depend on the individual treatment plan and should be followed precisely to ensure consistent drug levels.
What are the most serious risks associated with Mycophenolate Mofetil?+
Serious risks include opportunistic infections, bone‑marrow suppression leading to leukopenia or anemia, potential development of malignancies, severe liver injury, and rare neurological complications such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for these events.
Who should not use Mycophenolate Mofetil Tillomed?+
The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or any component of the formulation, and patients with active, uncontrolled infections. Caution is also advised for those with severe renal impairment or hepatic dysfunction.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mycophenolate Mofetil
Route
Oral Use
Manufacturer
Tillomed Laboratories Ltd
Origin
EU

Related products

CellCept 250 mg/1

CellCept 250 mg/1

Mycophenolate Mofetil · 250 mg

CellCept
CAPSULE
Genentech, Inc.
USA
CellCept 250 mg/1

CellCept 250 mg/1

Mycophenolate Mofetil · 250 mg

CellCept
CAPSULE
Genentech, Inc.
USA
CellCept 500 mg/1

CellCept 500 mg/1

Mycophenolate Mofetil · 500 mg

CellCept
TABLET, FILM COATED
Genentech, Inc.
USA
CellCept 500 mg/1

CellCept 500 mg/1

Mycophenolate Mofetil · 500 mg

CellCept
TABLET, FILM COATED
Genentech, Inc.
USA